Novartis To Appeal NICE's Rejection Of Lucentis For Diabetic Macular Edema
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE, the U.K.'s cost regulator, fails to recommend Novartis' Lucentis for diabetic macular edema in final draft guidance; Swiss company to appeal.